[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Gupta MD, Chakrabarti N, Agrawal P, Narurkar S: Angiosarcoma of the scalp. Indian J Plast Surg; 2009 Jan-Jun;42(1):118-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiosarcoma is a relatively rare soft tissue tumour.
  • It usually occurs in the head and neck, and especially in the scalp, in elderly people.
  • The treatment depends on the extent of the disease.
  • Radiotherapy and chemotherapy are advocated in the recurrent or extensive lesions with regional or distant metastasis.
  • The patient was not given postoperative radiotherapy or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):983-96 [16006792.001]
  • [Cites] Arch Dermatol. 1980 Jun;116(6):683-6 [7189653.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1907-21 [7197190.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):451-4 [7977971.001]
  • [Cites] J Cancer Res Clin Oncol. 2001;127(6):396-9 [11414200.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Sep;14(5):412-5 [11305388.001]
  • [Cites] Jpn J Clin Oncol. 2003 Apr;33(4):198-201 [12810835.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1046-57 [3815265.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):319-27 [8625109.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 Nov;106(11):943-51 [9373085.001]
  • (PMID = 19881033.001).
  • [ISSN] 1998-376X
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2772288
  •  go-up   go-down


2. Chakrabarti B, Ghosh SK, Basu B, Gupta P, Ghorai S, Ray SG, Das C: Non-adenomatous non-epithelial carcinoma (hemangiopericytoma) of prostate treated with conservative surgery followed by adjuvant chemoradiation. Curr Oncol; 2009 Aug;16(4):71-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiopericytoma is a malignant vascular tumour of soft tissue.
  • Microscopically, the tumour shows tightly packed cellular areas surrounding thin-walled branching blood vessels.
  • The feasibility of managing such a case with a combination of conservative surgery and adjuvant anti-malignancy treatment is unexplored.
  • Here, we report a case of hemangiopericytoma of the prostate treated with local excision, with preservation of prostate, followed by adjuvant radiotherapy (40 Gy in 20 fractions to pelvis followed by 24 Gy in 12 fractions as boost to prostate) and chemotherapy (doxorubicin and iphosphamide).
  • Post-treatment computed tomography scan after 4 weeks showed regression of pelvic lymph nodes and a normal-appearing prostate.
  • Levels of serum prostate-specific and carcinogenic embryonic antigen were normal throughout the period of treatment.
  • To date, followup has been uneventful, except for occasional bouts of diarrhea.We conclude that conservative surgery followed by adjuvant radiation and chemotherapy, with subsequent close follow-up, may adequately control localized disease in selected cases of hemangiopericytoma of the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1976;8(4):281-6 [948196.001]
  • [Cites] Laryngoscope. 1978 Jun;88(6):1006-12 [651500.001]
  • [Cites] Arch Otolaryngol. 1971 Apr;93(4):345-53 [5548984.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] BJU Int. 2005 May;95(7):943-7 [15839909.001]
  • [Cites] Br J Urol. 1998 Feb;81(2):329-30 [9488086.001]
  • [Cites] J Oral Maxillofac Surg. 1996 Aug;54(8):1020-3 [8765393.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Oct;34(5):454-6 [8909742.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1196-204 [8827025.001]
  • [Cites] Otolaryngol Head Neck Surg. 1996 Feb;114(2):339-40 [8637767.001]
  • [Cites] Rev Med Chil. 1993 Nov;121(11):1305-8 [8191139.001]
  • [Cites] Ital J Orthop Traumatol. 1988 Jun;14(2):167-73 [3220722.001]
  • [Cites] Hinyokika Kiyo. 1984 Jul;30(7):931-4 [6507209.001]
  • [Cites] J Surg Oncol. 1987 May;35(1):42-3 [3573772.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1985 Aug;86(8):959-65 [4058416.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • (PMID = 19672428.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2722051
  • [Keywords] NOTNLM ; Carcinoma / hemangiopericytoma / prostate / treatment
  •  go-up   go-down


3. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer; 2003 Nov 3;89(9):1620-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
  • The objective of the present study was to validate the use of intralesional injection of interleukin-2 (IL-2) in patients with skin and soft-tissue melanoma metastases.
  • A total of 24 patients with AJCC stage III or IV melanoma and single or multiple skin and soft-tissue metastases were included.
  • Interleukin-2 injections were administered intralesionally into the total number of cutaneous and soft-tissue metastases accessible from the skin, 2-3 times weekly, over 1-57 weeks.
  • The therapy was generally well tolerated; the observed adverse events were mainly of grade 1-2 severity.
  • Immunohistochemical studies showed the tumour cells undergoing apoptosis and revealed a mixed character of the inflammatory infiltrate.
  • The unusual high CR rate in metastatic melanoma of 62.5% and the limited toxicity suggest that treatment of skin and soft-tissue melanoma metastases with intralesional injection of IL-2 may be a safe and effective alternative to conventional therapies.
  • The optimal dosage and duration of this therapy still remain to be defined in larger prospective multicentre trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interleukin-2 / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Female. Humans. Immunohistochemistry. Injections, Intralesional. Male. Microscopy, Confocal. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):148-57 [9655305.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):532-7 [10404067.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1276-7 [10522685.001]
  • [Cites] Dermatol Clin. 2000 Jan;18(1):157-67 [10626121.001]
  • [Cites] J Am Acad Dermatol. 2000 Mar;42(3):480-9 [10688721.001]
  • [Cites] Arch Dermatol. 2000 Mar;136(3):428-30 [10724220.001]
  • [Cites] Folia Biol (Praha). 1999;45(6):227-31 [10732718.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1703-9 [10738230.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1267-72 [10778950.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):581-601 [10836008.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):167-85; quiz 186-8 [10906637.001]
  • [Cites] Dermatol Surg. 2000 Nov;26(11):1037-40 [11096390.001]
  • [Cites] Clin Exp Dermatol. 2001 Jan;26(1):42-4 [11260177.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3477-82 [11481353.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1071-4 [3342367.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;29(2):167-71 [1760862.001]
  • [Cites] Hautarzt. 1992 Jan;43(1):16-21 [1612904.001]
  • [Cites] Arch Dermatol. 1992 Aug;128(8):1127-8 [1323244.001]
  • [Cites] Br J Dermatol. 1992 Oct;127(4):442-3 [1419766.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5654-62 [8242620.001]
  • [Cites] Br J Dermatol. 1994 Apr;130(4):541-2 [8186129.001]
  • [Cites] Hautarzt. 1994 Aug;45(8):536-40 [7960753.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1353-7 [8915314.001]
  • [Cites] J Immunother. 1997 Mar;20(2):158-63 [9087388.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Apr;118(4):496-503 [9560102.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1752-9 [9586888.001]
  • [Cites] J Dermatol. 1998 Sep;25(9):569-72 [9798342.001]
  • (PMID = 14583759.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  • [Other-IDs] NLM/ PMC2394422
  •  go-up   go-down


Advertisement
4. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA: The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet; 2005 Sep;42(9):694-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
  • BACKGROUND: MDM2 acts as a principal regulator of the tumour suppressor p53 by targeting its destruction through the ubiquitin pathway.
  • Furthermore, SNP309 was proposed to be associated with accelerated soft tissue sarcoma formation in both hereditary (Li-Fraumeni) and sporadic cases in humans.
  • METHODS: We evaluated the possible contribution of SNP309 to three tumour types known to be linked with the MDM2/p53 pathway, using genomic sequencing or restriction fragment length polymorphism as screening methods.
  • Three separate Finnish tumour materials (population based sets of 68 patients with early onset uterine leiomyosarcomas and 1042 patients with colorectal cancer, and a series of 162 patients with squamous cell carcinoma of the head and neck) and a set of 185 healthy Finnish controls were analysed for SNP309.
  • Female SNP309 carriers were diagnosed with colorectal cancer approximately 2.7 years earlier than those carrying the wild type gene.
  • However, no statistically significant association of SNP309 with patients' age at disease onset or to any other clinicopathological parameter was found in these three tumour materials.
  • CONCLUSION: SNP309 had no significant contribution to tumour formation in our materials.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Head and Neck Neoplasms / genetics. Leiomyosarcoma / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic. Proto-Oncogene Proteins c-mdm2 / genetics
  • [MeSH-minor] Adult. Aged. Cohort Studies. Evaluation Studies as Topic. Female. Humans. Male. Middle Aged. Risk. Uterine Neoplasms / drug therapy


5. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft tissue sarcomas in the head and neck region are rare and often present a difficult differential diagnosis.
  • The aim of our presentation is to point out the complexity of the diagnosis, treatment and follow up.
  • Four months beforehand, a benign fibrous histiocytoma (BFH) had been removed from the same location by excision biopsy with wide tumour-free resection margins.
  • Radical tumour resection was completed by extended parotidectomy and neck dissection; the skin defect was covered by a regional bi-lobed flap.
  • No adjuvant radio- or chemotherapy was administered.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


6. Thanni LO: Extremity haemangiopericytoma, a case report from Nigeria. Afr Health Sci; 2005 Sep;5(3):261-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytoma is an uncommon soft tissue sarcoma of vascular origin.
  • Wide surgical excision is the mainstay of treatment.
  • However, adjuvant radiotherapy and chemotherapy are desirable because the malignant nature of this tumour is frequently unpredictable.
  • Adjuvant therapy is recommended for metastases, recurrence and incomplete resection.
  • Long term follow up is essential in all cases as recurrence can occur several years after treatment.
  • Where little or no experience with managing this tumor exists, it is important to be aware of its clinical behaviour and the treatment options, hence this case reports.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Leg / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Formos Med Assoc. 2000 May;99(5):428-30 [10870335.001]
  • [Cites] Radiology. 1960 May;74:721-30 [13825130.001]
  • [Cites] Head Neck. 2004 Jun;26(6):544-9 [15162357.001]
  • [Cites] J Foot Ankle Surg. 2004 May-Jun;43(3):191-4 [15181437.001]
  • [Cites] J Reprod Med. 2004 May;49(5):404-7 [15214720.001]
  • [Cites] Tumori. 2004 Mar-Apr;90(2):265-8 [15237597.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):128-32 [4359454.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Am J Surg. 1979 Mar;137(3):413-6 [434338.001]
  • [Cites] Am J Surg. 1984 Sep;148(3):372-4 [6476228.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1989 Sep-Oct;127(5):611-5 [2596154.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 1998 Jun;46(6):523-5 [9720371.001]
  • [Cites] Int Orthop. 1999;23(3):184-6 [10486035.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):315-9 [15243738.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):159-66 [12860507.001]
  • (PMID = 16245998.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831924
  •  go-up   go-down


7. Kang MY, Holland JM, Stevens KR Jr: Cranial neuropathy following curative chemotherapy and radiotherapy for carcinoma of the nasopharynx. J Laryngol Otol; 2000 Apr;114(4):308-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathy following curative chemotherapy and radiotherapy for carcinoma of the nasopharynx.
  • Cranial nerve damage following head and neck radiotherapy is an unusual event.
  • Cranial neuropathy following concurrent chemotherapy and radiotherapy is unreported.
  • The authors report a case of a 54-year-old man treated with curative chemotherapy and radiotherapy for a stage III nasopharyngeal carcinoma who developed an unilateral hypoglossal nerve palsy five years after therapy.
  • Hypoglossal nerve injury occurring after head and neck radiotherapy is an indirect effect due to progressive soft tissue fibrosis and loss of vascularity.
  • Cranial nerve palsies, including damage to the hypoglossal nerve, can develop years after therapy with no evidence of tumour recurrence.
  • Chemotherapy and radiotherapy have improved progression-free and overall survival in advanced nasopharyngeal cancer.
  • As more patients achieve long-term tumour control following chemotherapy and radiotherapy, we must be cognizant of potential late injury to cranial nerves.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hypoglossal Nerve Diseases / etiology. Nasopharyngeal Neoplasms / therapy. Radiation Injuries / etiology. Radiotherapy, High-Energy / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845053.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


8. Bien E, Stachowicz-Stencel T, Balcerska A, Godzinski J, Kazanowska B, Perek-Polnik M, Madziara W, Rybczynska A, Kurylak A, Zalewska-Szewczyk B, Peregud-Pogorzelski J: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study. Eur J Cancer Care (Engl); 2009 Jul;18(4):411-20
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children.
  • Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006.
  • Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each).
  • All patients received supplementing chemotherapy with no response in four.
  • Three of five secondary tumour resections proved complete.
  • Relapsed patients received chemotherapy +/- radiotherapy and surgery (three).
  • The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Male. Poland / epidemiology. Prognosis. Radiotherapy. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490008.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Yang XJ, Zheng JW, Zhou Q, Ye WM, Wang YA, Zhu HG, Wang LZ, Zhang ZY: Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients. Int J Oral Maxillofac Surg; 2010 Jun;39(6):568-72
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients.
  • Angiosarcoma, also known as malignant hemangioendothelioma, is a rare and aggressive malignant vascular tumour arising from endothelial cells, which accounts for approximately 10% of soft tissue sarcomas in the head and neck.
  • Between October 1996 and July 2008, 10 patients were diagnosed with angiosarcomas (AS) in the head and neck region, 8 of whom were included in this study (there were 7 high-grade and 1 low-grade lesions).
  • Six patients were treated surgically with or without postoperative radiotherapy and/or chemotherapy.
  • Two patients had large and extensive lesions that were considered to be inoperable, they were given palliative chemotherapy and/or radiotherapy.
  • Of the 8 patients reviewed in this study, 5 died of local recurrence or distant metastasis with a survival time of 8-19 months, 2 patients are alive with disease and 1 patient is free of disease.
  • The predeliction for local recurrence and distant metastasis and the high-grade characteristics of this tumour seemed to be correlated to the poor prognosis, although the small number of patients prevented statistical analysis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Head and Neck Neoplasms / chemistry. Head and Neck Neoplasms / pathology. Hemangiosarcoma / chemistry. Hemangiosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Antigens, Neoplasm / analysis. Factor VIII / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413272.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 9001-27-8 / Factor VIII
  •  go-up   go-down


10. Golubicić I, Nikitović M, Bokun J, Gavrilović D, Radosević-Jelić Lj: [Role of radiotherapy in combined therapy of soft tissue sarcoma in children and adolescents]. Srp Arh Celok Lek; 2000 May-Jun;128(5-6):172-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of radiotherapy in combined therapy of soft tissue sarcoma in children and adolescents].
  • Over last decades with modern approach to combined treatment of soft tissue sarcoma in children and adolescents, with effective systemic chemotherapy and adequate local control most frequently with conservative surgery and radiotherapy, or radiotherapy alone, results of treatment from 20% of a three-year overall survival to 75% were improved significantly.
  • Nevertheless, combined treatment involves risk of acute radiation reactions and late side effects, so there is a need for precise radiotherapy planning with optimal schedule of fractionating, adequate radiation volume and optimal tumour dose.
  • The purpose of our study was to evaluate the results of combined treatment of soft tissue sarcoma, role of radiotherapy in local control use of the optimal tumour dose and assessment of acute radiation reactions in an examined group of patients.
  • The most frequent tumour sites were the head and neck and the extremities.
  • Forty patients had histological type--Rhabdomyosarcoma (Table 1).
  • All patients were treated with chemotherapy, and local therapy were surgery and radiotherapy or radiotherapy alone.
  • All 47 patients were treated with radiotherapy; in 37 patients as primary treatment and in 10 patients as therapy for local relapse.
  • Radiotherapy was planned according to tumour size, tumour site, age of the patient and type of surgery.
  • Tumour dose from 45 Gy to 60 Gy was given in cases with a residual tumour.
  • Lower tumour doses were used in cases of postoperative microscopic disease, in certain cases of local relapse treatment or when the size of residual tumour and patient's age allowed no delivery of higher tumour doses.
  • Standard fractionating regimen was given to all patients, with daily fractions from 150 cGy to 214 cGy, five times per week.
  • In the group of 47 patients who received radiotherapy, 24 patients received a tumour dose from 45 Gy to 60 Gy and 23 patients a tumour dose from 32 Gy to 45 Gy.
  • The group of patients treated without tumour dose more than 45 Gy had a significantly better overall survival rate (p = 0.002) (Figure 2).
  • Namely, in addition to the group irradiated with a tumour dose from 32 Gy to 45 Gy, because of the postoperative microscopic disease, certain number of patients was irradiated with a "lower" dose because of an objective impossibility to administer a "higher" dose or this dose was planned for palliative reasons.
  • The tumour dose of 45 Gy was delivered to 6 of 10 patients treated for local relapse.
  • The tumour dose of 45 Gy was also used in four patients in CS IV, in two subjects for local control and in two as a palliative treatment.
  • Seven patients in CS III received a tumour dose of 45 Gy, because the age of children, tumour site and tumour size permitted no higher tumour doses.
  • That is when planning an adequate local therapy one must have in mind the initial tumour size, type of administered systematic chemo
  • [MeSH-major] Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11089417.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] YUGOSLAVIA
  •  go-up   go-down


11. Miki Y, Ngan S, Clark JC, Akiyama T, Choong PF: The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol; 2010 Jul;36(7):678-83
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of size change of soft tissue sarcoma during preoperative radiotherapy.
  • AIM: To assess the significance of change in tumour size during preoperative radiotherapy in patients with soft tissue sarcoma (STS).
  • Patients with head and neck STS, or who received neoadjuvant chemotherapy were excluded.
  • A difference in excess of 10% of the greatest tumour diameter of the pre-radiotherapy and the post-radiotherapy MRI scans was considered as change in tumour size.
  • RESULTS: Increase in tumour size was noted in 28 patients (31%) (Group 1).
  • CONCLUSION: Increase in tumour size during preoperative radiotherapy for soft tissue sarcoma does not seem to associate with inferior local tumour control or compromise survival.
  • Lack of reduction in tumour size is not necessarily a sign of lack of response to preoperative radiotherapy.
  • [MeSH-major] Neoadjuvant Therapy / methods. Sarcoma / pathology. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose Fractionation. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Radiotherapy, Adjuvant. Survival Analysis. Thallium Radioisotopes. Treatment Outcome. Victoria

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20547446.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer; 2010 Aug;46(12):2206-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
  • We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types.
  • PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria.
  • They were 18years old, had a good performance status, adequate bone marrow, renal and liver function, measurable progressive disease and had completed other relevant systemic treatments >4weeks ago.
  • RESULTS: Seventy six patients were included, 71 started treatment and received a median number of two cycles (four in ovarian cancer).
  • CONCLUSIONS: BI 2536 showed limited antitumour activity according to the design of this trial in five different tumour types.
  • Derivatives of BI 2536 with a more favourable pharmacological profile are currently explored further in prospective studies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Neoplasms / drug therapy. Pteridines / administration & dosage
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Humans. Infusions, Intravenous. Male. Melanoma / drug therapy. Melanoma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Patient Compliance. Sarcoma / drug therapy. Sarcoma / metabolism. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471824.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BI 2536; 0 / Pteridines
  •  go-up   go-down


13. Kawabata M, Yoshifuku K, Sagara Y, Kurono Y: Ewing's sarcoma/primitive neuroectodermal tumour occurring in the maxillary sinus. Rhinology; 2008 Mar;46(1):75-8
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma/primitive neuroectodermal tumour occurring in the maxillary sinus.
  • Fiberscopic examination revealed the presence of a soft reddish mass in the middle meatus of the left nostril.
  • The lesion originated from the maxillary sinus and extended to the middle nasal meatus; bone destruction and invasion of the subcutaneous tissue of the cheek were noted.
  • The tumour cells were strongly positive for CD99 and reacted weakly with NSE however the cells were negative for synaptophysin, LCA and cytokeratin on immunohistochemical examination.
  • Based on these findings, the tumour was diagnosed as a Ewing's sarcoma/primitive neuroectodermal tumour.
  • The patient was treated with radiotherapy and combination chemotherapy; subsequently, the tumour's size decreased markedly.
  • After 20 months of follow-up, the patient showed no evidence of local tumour growth or metastasis.
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444498.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Luis ÁM, Aguilar DP, Martín JA: Multidisciplinary management of soft tissue sarcomas. Clin Transl Oncol; 2010 Aug;12(8):543-53
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of soft tissue sarcomas.
  • Musculoskeletal sarcomas are a heterogeneous group of malignant neoplasms derived from connective tissue.
  • The annual incidence in adults in Europe is around 14,000 new cases of soft tissue sarcomas (STS) and 4,800 new cases of bone sarcomas.
  • Musculoskeletal tumours arise anywhere in the body, although lower extremities are the most common site of appearance, followed by upper extremities, trunk, retroperitoneum and head and neck area.
  • The aim of treatment should be focused on four main aspects: improving survival, avoiding local recurrence, maximising organ function and, finally, minimising morbidity.
  • Surgery, radiotherapy and, sometimes though increasingly, chemotherapy are the pillars on which rests the modern treatment of sarcomas.
  • The optimal management of musculoskeletal tumour requires a multidisciplinary integration of these different approaches in treatment planning right from the initial diagnoses.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Humans. Patient Care Team

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1975 Nov;182(5):597-602 [1190864.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1033-43 [11240245.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4472-7 [12431971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):203-9 [19679403.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):629-46, viii [18514703.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):174-9 [12851842.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):328-36; discussion 336-8 [1929613.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):165-72 [15021149.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):969-76 [7607971.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):553-7 [9250737.001]
  • [Cites] Cancer Treat Rev. 2008 Jun;34(4):339-47 [18313854.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):773-9 [16682152.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):396-408 [10023708.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] Radiother Oncol. 1996 Dec;41(3):209-14 [9027935.001]
  • [Cites] Acta Orthop Scand. 1990 Dec;61(6):475-86 [2281753.001]
  • [Cites] Recent Results Cancer Res. 2009;179:211-28 [19230542.001]
  • [Cites] Strahlenther Onkol. 2004 Jun;180(6):365-70 [15175871.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1146-53 [18394818.001]
  • [Cites] J Vasc Interv Radiol. 1992 Nov;3(4):659-63 [1332791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1729-34 [3759524.001]
  • [Cites] J Bone Joint Surg Am. 1976 Apr;58(3):317-27 [177425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):158-63 [17084545.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1197-205 [18224666.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1416-23 [16413697.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):825-30 [6735766.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):739-47 [14529779.001]
  • [Cites] Sarcoma. 2000;4(3):103-12 [18521288.001]
  • [Cites] Arch Surg. 1981 Jun;116(6):765-9 [7235973.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Aug;59(2):106-15 [16844383.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):475-9 [4005809.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Radiother Oncol. 2003 Jun;67(3):331-7 [12865183.001]
  • [Cites] Ann Surg. 1992 Mar;215(3):269-75 [1543400.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):650-5 [8642020.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):127-31 [11316555.001]
  • [Cites] Eur J Surg Oncol. 1991 Feb;17(1):71-80 [1995362.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):278-9 [7749711.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):458-64 [17363186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1051-8 [11072162.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):676-81 [14511617.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):573-81 [18521899.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Sarcoma. 1998;2(3-4):183-91 [18521252.001]
  • [Cites] BMJ. 1998 Jul 11;317(7151):93-4 [9657781.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):773-83 [17714991.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):852-9 [16199316.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):473-8 [8636760.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1818-29 [2121910.001]
  • [Cites] Cancer Control. 2005 Jan-Feb;12(1):27-35 [15668650.001]
  • [Cites] Clin Transl Oncol. 2008 Feb;10(2):102-10 [18258509.001]
  • [Cites] Sarcoma. 2002;6(1):5-18 [18521341.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):157-63 [10758318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):469-75 [11872294.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:4-8 [9057580.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jul;75(4):658-60 [8331127.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Ann Oncol. 2010 May;21 Suppl 5:v198-203 [20555081.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Sarcoma. 2006;2006(1):91671 [17040093.001]
  • [Cites] Cancer. 1975 Aug;36(2):759-64 [1157035.001]
  • [Cites] Cancer Treat Rev. 1977 Jun;4(2):67-86 [329988.001]
  • [Cites] Sarcoma. 2010;2010:506182 [20634933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):129-34 [7995743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1439-45 [15817348.001]
  • [Cites] Ann Oncol. 1992 Apr;3 Suppl 2:S57-8 [1622868.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):598-602 [17183556.001]
  • (PMID = 20709652.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  •  go-up   go-down


15. Guida M, Porcelli G, Ruggieri E, Zito A, Mattioli V, Montemurro S, Colucci G: Electrochemoterapy (ECT) for the treatment of superficial tumor localizations. J Clin Oncol; 2009 May 20;27(15_suppl):e13526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemoterapy (ECT) for the treatment of superficial tumor localizations.
  • : e13526 Background: ECT is an effective local treatment for palliation on inoperable superficial neoplastic lesions from any type of tumour.
  • It combines chemotherapy and electric pulses that permeabilize the cell membrane in a transient and reversible manner, allowing low-perrneant drugs to enter the cell, thus magnifying their cytotoxicity.
  • Recent1y, a new device (Clinoporetor, IGEA-Srl, Italy) has been developed to supply electric pulses with appropriate parameters permitting the clinical use of ECT.
  • METHODS: We treated 26 pts, M/F 12/14; median age 61 yrs, range 38-87: 7 breast cancer with nodular or infiltrating lesions in thoracic or abdominal wall; 12 melanoma (2 wide infiltration of thoracic wall, 10 in transit metastases or loco-regional recurrences); 2 head-neck cancer with a wide neck-scalp infiltration; 3 lymphomas with cutaneous lesions, 1 soft tissue sarcoma with a subcutaneous recurrence, 1 gastric cancer with 2 cutaneous localizations.
  • Intravenous bleomycin (15 mg/m<sup>2</sup>) were used in all patient; electric pulses were than applied to the tumor areas by needle electrodes in a time window of 20 minutes.
  • RESULTS: Treatment was safe and well tolerated, particularly when general anaesthesia was used.
  • Some pts showed a response after the second procedure.
  • Concomitant systemic treatment, no rapid spreading of the disease and surgical debulking were related to a better local control and survival.
  • CONCLUSIONS: ECT is a promising and safe treatment for superficial lesions from different malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Stachowicz-Stencel T, Bień E, Stefanowicz J, Połczytńska K, Sierota D, Szołkiewicz A, Drozyńska E, Kosiak W, Stankiewicz C, Pietniczka M, Kukwa A, Czauderna P, Balcerska A: [Diagnostic and therapeutic difficulties in soft tissue sarcomas localized in nonparameningeal head and neck region--own experiences]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):487-94
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and therapeutic difficulties in soft tissue sarcomas localized in nonparameningeal head and neck region--own experiences].
  • INTRODUCTION: Soft tissue sarcomas (MTM) localized within the nonorbital and non-parameningeal head and neck region in children are associated with favourable prognosis.
  • However in our material we have observed many therapeutic failures in this group of patients.
  • The aim of the study was to analyze the reasons for disappointing results of oncological therapy in children with MTM treated between 1992 and 2004.
  • Five patients were diagnosed with rhabdomyosarcoma, four--with non-rhlabdomyosarcoma, including: angiosarcoma, malignant triton tumour, fibrosarcoma and leiomyosarcoma.
  • The first sign of the neoplastic disease in all children was tumour.
  • In as many as five of nine patients initially a false histopathological diagnosis was made based on material obtained from aspiration biopsy of the tumour performed in non-oncological centres.
  • This resulted in a significant delay of the proper diagnosis of malignant disease ranging from 2 to 15 months (mean 7 months).
  • Therapy was conducted according to the schemes: MMT-89, CWS-91, CWS-96 and CWS-2002.
  • Durable complete remission after the first line therapy was obtained in one child only.
  • Six patients developed MTM relapse and two--progression during chemotherapy.
  • Finally five children remain disease-free after treatment termination with follow-up of 1 to 1,5 years.
  • Four of then had microscopically complete delayed resection of the tumour or the relapse.
  • Four patients died of neoplasm recurrence and progression.
  • In three of them the proper diagnosis was delayed significantly and they were diagnosed in the first or even second relapse of the tumour.
  • CONCLUSION: Unfavourable course and treatment results in MTM located in nonorbital and nonparameningeal head and neck region in our patients result from initial wrong histopathological diagnosis and delayed therapy institution.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / therapy. Hemangiosarcoma / diagnosis. Hemangiosarcoma / therapy. Humans. Infant. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719161.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Modritz D, Ladenstein R, Pötschger U, Amman G, Dieckmann K, Horcher E, Urban C, Meister B, Schmitt K, Jones R, Kaulfersch W, Haas H, Moser R, Stöllinger O, Peham M, Gadner H, Koscielniak E, Treuner J: Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr; 2005 Mar;117(5-6):196-209
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study.
  • OBJECTIVE: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy.
  • METHODS: Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age.
  • Local tumour control was ensured by surgery and risk-adapted radiotherapy.
  • 59/89 patients had localised RMS-like (rhabdomayosarcoma) STS (EFS 73% +/- 7%), 14 had localised NON-RMS STS (EFS 54% +/- 16%) and 15 patients had metastatic disease at diagnosis (EFS 33% +/- 12%), 1 patient had fibromatosis.
  • Favourable primary tumour sites of nonmetastatic RMS-like STS i.e. orbit, head/neck nonparameningeal or genitourinary non-bladder/prostate were diagnosed in 15 patients (1/15 patients died).
  • The most common treatment failure was local relapse occurring in 21% of patients in the high-risk group.
  • CONCLUSION: Risk-adapted individualisation of treatment led to a reduction of chemotherapy in the low and standard risk group without compromising survival.
  • These preliminary results after a median observation time of 2.5 years confirm the CWS 96 strategy.
  • [MeSH-major] Risk Assessment / methods. Sarcoma / mortality. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2005 Mar;117(5-6):176-9 [15875755.001]
  • (PMID = 15875759.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


18. Bruns F, Janssen S, Laenger F, Dobbelstein C, Meyer A: Extramedullary plasmocytoma: a rare case with bifocal manifestation at uncommon sites. Anticancer Res; 2010 May;30(5):1779-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As these tumours are rare and can present without a typical clinical picture, correct diagnosis is difficult to confirm, particularly when the lesions occur at uncommon sites.
  • Biopsy showed an anaplastic tumour which was first diagnosed as localised rhabdomyosarcoma; therefore, a combined approach with neoadjuvant radiotherapy followed by surgery was recommended.
  • CT and MRI of the head revealed a single brain lesion.
  • After comprehensive review of this specimen and the previous biopsy, the diagnosis was changed to anaplastic bifocal EMP.
  • Generalised myeloma was excluded; therefore the patient was treated with definitive radiotherapy of the left knee region and postoperative partial brain irradiation.
  • Unfortunately, the patient died several months later due to fulminant progressive disease at both treated sites despite rapidly initiated chemotherapy.
  • CONCLUSION: Correct diagnosis of EMP may be difficult, particularly as this disease is rare and can present with atypical clinical picture and immunophenotype.
  • Review of the specimen by a histopathologist with special interest in soft tissue tumours or lymphoproliferative disorders is strongly recommended.
  • [MeSH-major] Plasmacytoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Brain Neoplasms / diagnosis. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Fatal Outcome. Humans. Immunophenotyping. Knee / pathology. Lymphoproliferative Disorders / metabolism. Lymphoproliferative Disorders / pathology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Multiple Myeloma / pathology. Radiotherapy / methods. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592378.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • Paraffin embedded tumour specimens were immunohistochemically stained for S-100, p53 and Ki67/MIB-1.
  • Four tumours were localised at the head & neck region, three were found in the extremities and one tumour was located on the trunk.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • The Ki67/MIB-1 proliferation index was detectable in all tumour samples, it differed from 10-30%.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


20. Raguse JD, Gath HJ, Oettle H, Bier J: Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg; 2004 Sep;33(6):606-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive fibromatosis is the name for uncommon soft-tissue neoplasms arising within musculoaponeurotic tissue.
  • A slow but steady reduction of the tumour was observed, and pre-existing symptoms disappeared.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Fibromatosis, Aggressive / drug therapy. Head and Neck Neoplasms / drug therapy. Interferon-alpha / administration & dosage
  • [MeSH-minor] Female. Humans. Injections, Subcutaneous. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Recombinant Proteins

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15308262.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


21. Tormo V, Andreu FJ: Primary breast synovial sarcoma: a rare primary breast neoplasm. Clin Transl Oncol; 2009 Dec;11(12):854-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast synovial sarcoma: a rare primary breast neoplasm.
  • Synovial sarcomas account for about 6-9% of soft tissue sarcomas and most commonly develop in the extremity of young adults (80%).
  • The other 20% of synovial sarcomas can arise in non-extremity sites (trunk 8%, retroperitoneal/ abdominal 7%, head and neck 5%) but synovial sarcomas can develop in almost any other anatomical location.
  • We report a case of a young woman who presented with a suspected common breast tumour and started treatment of this tumour with carcinoma neoadjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2161-9 [8397060.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] J Pathol. 1999 Mar;187(4):490-6 [10398111.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • (PMID = 20045794.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Tomasini C, Grassi M, Pippione M: Cutaneous angiosarcoma arising in an irradiated breast. Case report and review of the literature. Dermatology; 2004;209(3):208-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiosarcoma (AS) is a rare, aggressive tumour of endothelial origin occurring in various clinical settings, including idiopathic AS on the head and neck in elderly people, lymphoedema-associated AS, post-irradiation AS, soft-tissue AS, and various others.
  • Despite the widespread use of radiation therapy in the treatment of breast carcinoma, AS developing in the wake of a radiation therapy is extremely infrequent.
  • Although there is little doubt that radiation in therapeutic doses can induce sarcomas, quantification of that risk is complicated by many variables, among them chronic lymphoedema.
  • The lesions developed 3 years after she had undergone ipsilateral quadrantectomy for an invasive ductal carcinoma followed by 25 tangent field radiotherapy sessions on the breast.
  • The oncological follow-up did not disclose local recurrence of the tumour or metastases of breast carcinoma.
  • The patient underwent monthly cycles of chemotherapy with intravenous doxorubicin with partial remission of the affected area after 24 months, followed by the occurrence of liver metastases and exitus 30 months after diagnosis.
  • Whereas the role of lymphoedema does not seem relevant to the pathogenesis of this malignancy, the association with chronic radiation dermatitis in our case reinforces the supposed role of radiation in the development of this tumour.
  • Onset of AS should be taken into consideration when treating patients who develop multiple lesions on the skin above the irradiated area, even many years after the therapy.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatology. 2004;209(3):175-6 [15459528.001]
  • (PMID = 15459534.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 79
  •  go-up   go-down


23. Mosca F, Stracqualursi A, Lipari G, Persi A, Latteri S: [Malignant stromal tumors of the duodenum. Report of a case]. Chir Ital; 2000 Nov-Dec;52(6):725-32
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Authors report a rare case of undifferentiated duodenal malignant stromal tumour in a 69-years-old man radically managed by pancreaticoduodenectomy and resection of a liver metastasis.
  • Several preoperative tests were performed (barium meal, endoscopy, ultrasonography and CT scan) but failed to yield a differential diagnosis between a tumour of the pancreatic head and a retroperitoneal neoplasm.
  • The diagnosis was only histological.
  • The tumour was considered to be high-grade due to its large size, high mitotic index, and the presence of necrosis and liver metastasis.
  • Thorough surveillance revealed several hepatic metastases 29 months after resection, and chemotherapy performed at this stage proved completely ineffective.
  • [MeSH-major] Duodenal Neoplasms / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200011.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer; 2003 Sep;39(13):1920-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
  • Yondelis (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies.
  • Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP).
  • Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent.
  • The combination of the two drugs produced a dramatic increase of survival lasting several months.
  • In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts.
  • The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dioxoles / administration & dosage. Dioxoles / adverse effects. Drug Synergism. Female. Humans. Isoquinolines / administration & dosage. Isoquinolines / adverse effects. Mice. Neoplasm Transplantation. Tetrahydroisoquinolines. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2003 Sep;39(13):1816-7 [12932657.001]
  • (PMID = 12932672.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Ayadi L, Chaabouni S, Chabchoub I, Ayadi A, Kallel R, Fakhfakh I, Hachicha M, Boudawara T: [Primary rhabdomyosarcoma of the pleura presenting as recurrent pneumothorax]. Rev Mal Respir; 2009 Mar;26(3):333-7
MedlinePlus Health Information. consumer health - Collapsed Lung.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Pneumothorax récidivant révélateur d'un rhabdomyosarcome primitif de la plèvre.
  • INTRODUCTION: Rhabdomyosarcoma is the most common soft tissue sarcoma in the first two decades of life.
  • Its most common location is the head and neck.
  • Our aim is to discuss the clinical presentation, treatment and prognosis of this uncommon location of rhabdomyosarcoma.
  • A computed tomography scan showed only pleural detachment with no evidence of any pleural disease.
  • Despite chemotherapy, the tumour quickly increased in size and the infant died from acute respiratory failure.
  • CONCLUSION: Thoracic rhabdomyosarcoma is rare and remains clinically silent for a long time.
  • [MeSH-major] Pleural Neoplasms / diagnosis. Pneumothorax / etiology. Rhabdomyosarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367209.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Boniver V, Moreau P, Lefebvre P: Synovial sarcoma of the larynx: case report and literature review. B-ENT; 2005;1(1):47-51
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial sarcoma is a rare mesenchymal malignancy which represents 8.5% of all soft tissue sarcomas and usually occurs in the lower extremities of young adults.
  • Because the incidence in the head and neck region is very low, only 13 patients with endolaryngeal localisation have been reported so far.
  • The tumour was completely resected, under suspension micro-laryngoscopy, using a CO2 laser.
  • Complete surgical excision is the treatment of choice.
  • The role of chemotherapy and radiotherapy is still debated.
  • However, this tumour has a poor prognosis because of the occurrence of distant metastasis.
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Laser Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999676.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 19
  •  go-up   go-down


27. Healy JN, Borg MF: Paediatric nasopharyngeal rhabdomyosarcoma: A case series and literature review. J Med Imaging Radiat Oncol; 2010 Aug;54(4):388-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue tumour in children, with the head and neck region accounting for 35-40% of cases.
  • Both the Intergroup Rhabdomyosarcoma Studies and the European Studies have established that the ideal management of this disease is multimodal, using a combination of surgery, chemotherapy and radiotherapy.
  • Management in all patients was multimodal, using a combination of chemotherapy, radiotherapy as well as surgery.
  • External beam radiotherapy is an integral component of treatment for nasopharyngeal RMSs.
  • Current advances in radiotherapy are aimed at improving the rate of tumour control and reducing such complications.
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718921.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  •  go-up   go-down


28. Siveke JT, Sen Gupta R, Rieckhoff KU, Braumann D, Goldmann T: [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor]. HNO; 2003 Oct;51(10):825-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor].
  • HISTORY AND DIAGNOSIS: A 59-year old engineer was admitted to the hospital because of pain in his right collar region and the onset of incomplete paresis of the right arm.
  • Magnetic resonance tomography displayed an advanced tumour arising from the right paravertebral soft tissue.
  • Histological examination revealed a malignant peripheral nerve sheath tumor (MPNST).
  • Thirteen years before admission, the patient had a right-sided tumor-tonsillectomy of a squamous cell carcinoma and local radiation of a cystic squamous cell carcinoma in the ipsilateral cervical soft tissue.
  • CLINICAL COURSE AND THERAPY: In the following course, progressive neurological symptoms occurred including beginning paraplegia, right phrenic paralysis and a severe concomitant pain syndrome.
  • Due to the location and advanced tumor state, surgical treatment was not performed and palliative chemotherapy remained ineffective.
  • Unusual neurological symptoms in anatomical regions of former radiation should therefore include neurogenic secondary malignancies in the differential diagnosis for early surgical intervention.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / diagnosis. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Nerve Sheath Neoplasms / diagnosis. Paraparesis / etiology. Radioisotope Teletherapy / adverse effects. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Arm / innervation. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Respiratory Paralysis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1247-53 [8435801.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1028-33 [6821867.001]
  • [Cites] Eur J Cancer. 1995;31A(1):31-4 [7695975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61 [10571202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 14523537.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement